Livzon Pharmaceutical Group Inc
SZSE:000513

Watchlist Manager
Livzon Pharmaceutical Group Inc Logo
Livzon Pharmaceutical Group Inc
SZSE:000513
Watchlist
Price: 37.92 CNY 0.72% Market Closed
Market Cap: 35B CNY
Have any thoughts about
Livzon Pharmaceutical Group Inc?
Write Note

Livzon Pharmaceutical Group Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Livzon Pharmaceutical Group Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Livzon Pharmaceutical Group Inc
SZSE:000513
Cash & Cash Equivalents
ÂĄ11.5B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
29%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
ÂĄ8.8B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
-9%
CAGR 5-Years
3%
CAGR 10-Years
24%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
ÂĄ391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Livzon Pharmaceutical Group Inc
Glance View

Market Cap
35B CNY
Industry
Pharmaceuticals

Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.

Intrinsic Value
47.84 CNY
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Livzon Pharmaceutical Group Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
11.5B CNY

Based on the financial report for Sep 30, 2024, Livzon Pharmaceutical Group Inc's Cash & Cash Equivalents amounts to 11.5B CNY.

What is Livzon Pharmaceutical Group Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
29%

Over the last year, the Cash & Cash Equivalents growth was 11%. The average annual Cash & Cash Equivalents growth rates for Livzon Pharmaceutical Group Inc have been 9% over the past three years , 10% over the past five years , and 29% over the past ten years .

Back to Top